Trial Profile
Sublingual Y-2(Edaravone And Borneol) Tablet For Acute Ischemic And Hemorrhagic Patients-the SALVAGE Trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Y-2 (Primary)
- Indications Intracranial haemorrhages; Stroke
- Focus Adverse reactions
- Acronyms SALVAGE
- Sponsors YenePharma
- 13 Feb 2020 Planned End Date changed from 1 Mar 2019 to 1 Feb 2021.
- 13 Feb 2020 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2020.
- 01 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.